Skip to main content

Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World

Drugs & Aging volume 37, pages 677–689 (2020)Cite this article

Abstract

Background

The role of platinum-based chemotherapy (PBC) for the treatment of older patients with non-small cell lung cancer (NSCLC) is still a matter of debate, despite the advent of immunotherapy.

Objective

The aim of the study was to identify factors associated with first-line PBC prescription and, secondly, to evaluate the impact of first-line PBC on survival, treatment intensity, risk of hospitalization, and subsequent treatments.

Patients and Methods

We reviewed a consecutive series of 474 older patients (age ≥ 70 years) diagnosed with stage IIIB–IV NSCLC at the Department of Oncology, University Hospital of Udine, Italy from January 2009 to March 2017.

Results

Overall, 198 patients were deemed eligible, and 65.2% received a PBC. At multivariate analysis, older age was the only factor associated with PBC prescription. In the whole cohort, 46 patients (23.2%) were hospitalized for chemotherapy-related toxicity. Both PBC prescription (odds ratio [OR] 2.23, 95% confidence interval [CI] 1.02–4.87, p = 0.04) and tumor burden (OR 2.39, 95% CI 1.07–5.32, p = 0.03) emerged as independent risk factors for hospitalization. Moving to significant predictors of patterns of care, Eastern Cooperative Oncology Group (ECOG) performance status > 0 was associated with greater risk of first-line failure (OR 2.20, 95% CI 1.15–4.20, p = 0.02), while bone metastases (OR 0.29, 95% CI 0.12–0.69, p = 0.005) and a Charlson Comorbidity Index score ≥ 3 (OR 0.40, 95% CI 0.19–0.84, p = 0.016) independently predicted lower probability of receiving second-line therapy. Remarkably, PBC did not significantly impact overall survival (hazard ratio [HR] 0.83, 95% CI 0.61–1.14, p = 0.24) and progression-free survival (HR 0.95, 95% CI 0.70–1.28, p = 0.73) compared to single-agent chemotherapy (SAC). However, according to an exploratory landmark analysis, patients who received four cycles of treatment or maintenance therapy experienced prolonged overall survival, regardless of PBC use.

Conclusions

This study evaluated the real-world use of PBC in older patients with NSCLC, offering an insight into the determinants of its prescription and the pattern of care of these patients. Of note, PBC use was associated with a higher likelihood of hospitalization for chemotherapy-related toxicity, with no benefit on survival compared to SAC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Availability of Data and Material

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Wiley. 2018;68:394–424.

    Article  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.

  3. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237.

  4. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Corrigendum: metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):863–70. https://doi.org/10.1093/annonc/mdy474.

    CAS  Article  PubMed  Google Scholar 

  5. Denson AC, Mahipal A. Participation of the Elderly Population in Clinical Trials: Barriers and Solutions. Cancer Control. 2014. https://doi.org/10.1177/107327481402100305.

    Article  PubMed  Google Scholar 

  6. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26(2):288–300. https://doi.org/10.1093/annonc/mdu210.

    CAS  Article  PubMed  Google Scholar 

  7. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36:2326–47.

    Article  Google Scholar 

  8. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.

    CAS  Article  Google Scholar 

  9. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012. https://doi.org/10.1016/S1470-2045(12)70259-0.

    Article  PubMed  Google Scholar 

  10. Corre R, Greillier L, Le Caër H, Audigier-Valette C, Baize N, Bérard H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08–02 study. J Clin Oncol. 2016;34:1476–83.

    CAS  Article  Google Scholar 

  11. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

    CAS  Article  Google Scholar 

  12. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

    CAS  Article  Google Scholar 

  13. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.

    CAS  Article  Google Scholar 

  14. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51.

    CAS  Article  Google Scholar 

  15. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.

    CAS  Article  Google Scholar 

  16. Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019;75:39–51. https://doi.org/10.1016/j.ctrv.2019.03.004.

    CAS  Article  PubMed  Google Scholar 

  17. Vecchiarelli S, Bennati C. Oncogene addicted non-small-cell lung cancer: current standard and hot topics. Future Oncol. 2018;14:3–17.

    CAS  Article  Google Scholar 

  18. Santos FN, de Castria TB, Cruz MRS, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Sao Paulo Med J. 2016;134:465–6.

    Article  Google Scholar 

  19. Sacco PC, Maione P, Palazzolo G, Gridelli C. Treatment of advanced non-small cell lung cancer in the elderly. Expert Rev Respir Med. 2018;12(9):783–92. https://doi.org/10.1080/17476348.2018.1510322.

    CAS  Article  PubMed  Google Scholar 

  20. Santos ES. Treatment options after first-line immunotherapy in metastatic NSCLC. Expert Rev Anticancer Ther. 2020;20:221–8.

    CAS  Article  Google Scholar 

  21. Mhanna L, Guibert N, Milia J, Mazieres J. When to consider immune checkpoint inhibitors in oncogene-driven non-small cell lung cancer? Curr Treat Options Oncol. 2019;20:1–11.

    Article  Google Scholar 

  22. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191–7.

    Article  Google Scholar 

  23. Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am Soc Clin Oncol Educ Book. 2018;38:400–14. https://doi.org/10.1200/EDBK_201435.

    Article  PubMed  Google Scholar 

  24. Sgambato A, Casaluce F, Gridelli C. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Expert Opin Biol Ther. 2017;17(5):565–71. https://doi.org/10.1080/14712598.2017.1294157.

    CAS  Article  PubMed  Google Scholar 

  25. Gridelli C, Sgambato A. Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe? Ann Transl Med. 2019;7:S282–S282282.

    Article  Google Scholar 

  26. Almodovar T, Teixeira E, Barroso A, Soares M, Queiroga HJ, Cavaco-Silva J, et al. Elderly patients with advanced NSCLC: the value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity. Pulmonology. 2019;25:40–50.

    CAS  Article  Google Scholar 

  27. Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol. 2010;21:1825–33.

    CAS  Article  Google Scholar 

  28. Kravchenko J, Berry M, Arbeev K, Kim Lyerly H, Yashin A, Akushevich I. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer. 2015;88:85–93.

    Article  Google Scholar 

  29. Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J. Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer. 2018;19:e163–e169169.

    Article  Google Scholar 

  30. Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014;25:1821–9.

    CAS  Article  Google Scholar 

  31. Califano R, Gomes F, Ackermann CJ, Rafee S, Tsakonas G, Ekman S. Immune checkpoint blockade for non–small cell lung cancer: what is the role in the special populations? Eur J Cancer. 2020;125:1–11.

    CAS  Article  Google Scholar 

  32. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group Trials. J Clin Oncol. 2008;26:54–9.

    CAS  Article  Google Scholar 

  33. Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, et al. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol. 2018;36:2585–92.

    CAS  Article  Google Scholar 

  34. Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.

    CAS  Article  Google Scholar 

  35. Santos FN, de Castria TB, Cruz MRS, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database Syst Rev. 2015;2015(10):CD010463. https://doi.org/10.1002/14651858.CD010463.pub2.

    Article  PubMed Central  Google Scholar 

  36. Tivey A, Ullah M, Beech A, Ng C, Cove-Smith L. Can frailty screening tools predict completion of chemotherapy and chemotherapy toxicity in patients with thoracic malignancy? J Geriatr Oncol. 2020;S1879–4068(19):31627–3. https://doi.org/10.1016/j.jgo.2020.03.002.

    Article  Google Scholar 

  37. Decoster L, Schallier D. Treatment of older patients with advanced non-small cell lung cancer: a challenge. J Geriatric Oncol. 2019;10:528–33.

    Article  Google Scholar 

  38. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

    CAS  Article  Google Scholar 

  39. Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, et al. Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous non-small cell lung cancer. Am J Clin Oncol Cancer Clin Trials. 2016;39:441–7.

    CAS  Article  Google Scholar 

  40. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medicine (DAME), University of Udine, 33100, Udine, Italy

    Giacomo Pelizzari, Francesco Cortiula, Marco Giavarra, Michele Bartoletti, Camilla Lisanti, Vanessa Buoro, Monica Cattaneo & Fabio Puglisi

  2. Department of Oncology, Santa Maria Della Misericordia Hospital (ASUFC), 33100, Udine, Italy

    Giacomo Pelizzari, Francesco Cortiula, Marco Giavarra, Michele Bartoletti, Camilla Lisanti, Vanessa Buoro, Monica Cattaneo, Ciro Rossetto, Simona Rizzato, Marianna Macerelli, Gianpiero Fasola & Alessandro Follador

  3. Dipartimento Di Oncologia Medica, Oncologia Medica E Prevenzione Oncologica, Centro Di Riferimento Oncologico Di Aviano (CRO), IRCCS, 33081, Aviano, Italy

    Fabio Puglisi

Authors
  1. Giacomo Pelizzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Cortiula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Giavarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michele Bartoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Camilla Lisanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vanessa Buoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Monica Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ciro Rossetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Simona Rizzato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fabio Puglisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marianna Macerelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gianpiero Fasola
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alessandro Follador
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GP contributed to the concept and design of the study, acquisition of data, statistical analysis, and interpretation of data. Furthermore, he contributed to the drafting and revision of the article and the final approval of the version to be published. FC, MG, MC, and CL contributed to the acquisition of data and drafting of the article. MB and VB contributed to the drafting of the article. CR, SR, FP, and MM contributed to the revision of the article. GF and AF contributed to the concept and design of the study, interpretation of data, revision of the article, and the final approval of the version to be published. All authors have seen and approved the final manuscript.

Corresponding author

Correspondence to Giacomo Pelizzari.

Ethics declarations

Funding

No external funding was used in the preparation of this article.

Conflict of interest

AF declares honoraria for advisory boards from Astrazeneca and MSD, and reports travel expenses from Roche, MSD, and Eisai. FP declares honoraria for advisory boards, activities as a speaker, and travel expenses from Amgen, Astrazeneca, Celgene, Eisai, Eli Lilly, Ipsen, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, and Takeda, and reports research funding from Astrazeneca, Roche, and Eisai. GP, FC, MG, MB, CL, VB, MC, CR, SR, MM, and GF declare that they have no conflicts of interest that might be relevant to the contents of this article.

Ethics approval

The study was approved by the Internal Review Board of the Department of Oncology, University Hospital of Udine, and by the regional ethics committee (N° Protocol 22,651, ratified in September 2017).

Consent to participate

Informed consent was obtained for the use of clinical data, rendered anonymous, for purposes of clinical research, epidemiology, training, and study of diseases.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 615 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pelizzari, G., Cortiula, F., Giavarra, M. et al. Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs Aging 37, 677–689 (2020). https://doi.org/10.1007/s40266-020-00785-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-020-00785-8